Generation of stable cell lines expressing lamivudine-resistant hepatitis B virus for antiviral-compound screening

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 6, 2003, Pages 1936-1942

  Walters, Kathie Anne ^a   Tipples, Graham A ^b   Allen, Marchelle I ^c   Condreay, Lynn D ^c   Addison, William R ^a   Tyrrell, Lorne ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; CARBOCYCLIC 2' DEOXYGUANOSINE; DEOXYGUANOSINE DERIVATIVE; LAMIVUDINE; PENCICLOVIR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; DNA INTEGRATION; DNA SEQUENCE; DRUG DETERMINATION; DRUG RESISTANCE; DRUG SCREENING; DRUG SENSITIVITY; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS RECOMBINANT;

ACYCLOVIR; ANTIVIRAL AGENTS; BASE SEQUENCE; DEOXYGUANOSINE; DIDEOXYNUCLEOSIDES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0038440787     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.6.1936-1942.2003     Document Type: Article

References (58)

1. Addison, W. R., K. A. Walters, W. W. Wong, J. S. Wilson, D. Madej, L. D. Jewell, and D. L. Tyrrell. 2002. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J. Virol. 76:6356-6363.
2. Allen, M., M. Deslauriers, C. Andrews, G. Tipples, K. Walters, D. Tyrrell, N. Brown, L. Condreay et al. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
3. Bain, V., N. Kneteman, M. Ma, K. Gutfreund, J. Shapiro, K. Fischer, G. Tipples, H. Lee, L. Jewell, and D. Tyrrell. 1996. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62:1456-1462.
4. Beasley, R. 1988. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
5. Beasley, R., L. Hwang, C. Lin, and C. Chien. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet ii:1129-1133.
6. Ben-Ari, Z., O. Pappo, R. Zemel, E. Mor, and R. Tur-Kaspa. 1999. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 68:232-236.
7. Ben-Ari, Z., D. Shmueli, E. Mor, E. Shaharabani, N. Bar-Nathan, Z. Shapira, and R, Tur-Kaspa. 1997. Beneficial effect of lamivudine pre- and postliver transplantation for hepatitis B infection. Transplant. Proc. 29:2687-2688.
8. Ben-Ari, Z., D. Shmueli, E. Mor, Z. Shapira, and R. Tur-Kaspa. 1997. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63:393-396.
9. Bishop, N., G. Civitico, Y. Wang, K. Guo, C. Birch, I. Gust, and S. Locarnini. 1990. Antiviral strategies in chronic hepatitis B virus infection. I. Establishment of an in vitro system using the duck hepatitis B virus model. J. Med. Virol. 31:82-89.
10. Boucher, C., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. Wainberg, and J. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
11. Chang, C., S. Doong, J. Zhou, J. Beach, L. Jeong, C. Chu, C. Tsai, Y. Cheng, D. Liotta, and R. Schinazi. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
12. Chang, C., V. Skalski, J. Zhou, and Y. Cheng. 1992. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:22414-22420.
13. Daluge, S., S. Good, M. Faletto, W. Miller, M. S. Clair, L. Boone, M. Tisdale, N. Parry, J. Reardon, R. Dornsife, D. Averett, and T. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective antihuman immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
14. Delaney, W. E., IV, R. Edwards, D. Colledge, T. Shaw, J. Torresi, T. G. Miller, H. C. Isom, C. T. Bock, M. P. Manns, C. Trautwein, and S. Locarnini. 2001. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob. Agents Chemother. 45:1705-1713.
15. Dienstag, J., E. Schiff, T. Wright, R. Perrillo, H. Hann, Z. Goodman, L. Crowther, L. Condreay, M. Woessner, M. Rubin, and N. Brown. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
16. Doong, S., C. Tsai, R. Schinazi, D. Liotta, and Y. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
17. Fischer, K., and D. Tyrrell. 1996. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine)] in vitro. Antimicrob. Agents Chemother. 40:1957-1960.
18. Fu, L., and Y.-C. Cheng. 2000. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob. Agents Chemother. 44:3402-3407.
19. Grellier, L., D. Mutimer, M. Ahmed, D. Brown, A. Burroughs, K. Rolles, P. McMaster, P. Beranek, F. Kennedy, H. Kibbler, P. McPhillips, E. Elias, and G. Dusheiko. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
20. Gutfreund, K., M. Williams, R. George, V. Bain, M. Ma, E. Yoshida, J. Villeneuve, K. Fischer, and D. Tyrrell. 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J. Hepatol. 33:469-475.
21. Howe, A. Y., M. J. Robins, J. S. Wilson, and D. L. Tyrrell. 1996. Selective inhibition of the reverse transcription of duck hepatitis B virus by binding of 2′,3′-dideoxyguanosine 5′-triphosphate to the viral polymerase. Hepatology 23:87-96.
22. Jansen, R., L. Johnson, and D. Averett. 1993. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob. Agents Chemother. 37:441-447.
23. King, R., S. Garber, D. Winslow, C. Reid, L. Bacheler, E. Anton, and M. Otto. 1995. Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antivir. Chem. Chemother. 6:80-88.
24. Korba, B., and M. Boyd. 1996. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. 40:1282-1284.
25. Ladner, S., T. Miller, and R. King. 1998. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42:2128-2131.
26. Ladner, S., T. Miller, M. Otto, and R. King. 1998. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir. Chem. Chemother. 9:65-72.
27. Lai, C., R. Chien, N. Leung, T. Chang, R. Guan, D. Tai, K. Ng, P. Wu, J. Dent, J. Barber, L. Stephenson, D. Gray, et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
28. Lai, C., C. Ching, A. Tung, E. Li, J. Young, A. Hill, B. Wong, J. Dent, and P. Wu. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
29. Lee, B., W. Luo, S. Suzuki, M. J. Robins, and D. L. J. Tyrrell. 1989. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. 33:336-339.
30. Liaw, Y., R. Chien, C. Yeh, S. Tsai, and C. Chu. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
31. Ling, R., and T. Harrison. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J. Gen. Virol. 80:601-606.
32. Ling, R., D. Mutimer, M. Ahmed, E. Boxall, E. Elias, G. Dusheiko, and T. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
33. Maynard, J. 1990. Hepatitis B: global importance and need for control. Vaccine 8(Suppl.):S18-S20.
34. McCaughan, G., J. Spencer, D. Koorey, S. Bowden, A. Bartholomeusz, M. Littlejohn, D. Verran, A. Chui, A. Sheil, R. Jones, S. Locarnini, and P. Angus. 1999. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant. Surg. 5:512-519.
35. Melegari, M., P. Scaglioni, and J. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
36. Moraleda, G., J. Saputelli, C. Aldrich, D. Averett, L. Condreay, and W. Mason. 1997. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:9392-9399.
37. Nery, J., D. Weppler, M. Rodriguiz, P. Ruiz, E. Schiff, and A. Tzakis. 1998. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65:1615-1621.
38. Ono-Nita, S., N. Kato, Y. Shiratori, K. Lan, H. Yoshida, F. Carrilho, and M. Omata. 1999. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J. Clin. Investig. 103:1635-1640.
39. Ono-Nita, S., N. Kato, Y. Shiratori, T. Masaki, K. Lan, F. Carrilho, and M. Omata. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
40. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, New York, N.Y.
41. Schinazi, R., G. Gosselin, A. Faraj, B. Korba, D. Liotta, C. Chu, C. Mathe, J. Imbach, and J. Sommadossi. 1994. Pure nucleoside enantiomers of beta-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 38:2172-2174.
42. Schuurman, R., M. Nijhuis, R. V. Leeuwen, P. Schipper, D. de Jong, P. Collis, S. Danner, J. Mulder, C. Loveday, and C. Christopher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
43. Seifer, M., K. Heermann, and W. Gerlich. 1990. Replication of hepatitis B virus in transfected nonhepatic cells. Virology 179:300-311.
44. Sells, M., M. Chen, and G. Acs. 1987. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84:1005-1009.
45. Severini, A., X.-Y. Liu, J. S. Wilson, and D. L. J. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
46. Stuyver, L. J., S. A. Locarnini, A. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
47. Suzuki, S., B. Lee, W. Luo, D. Tovell, M. Robins, and D. Tyrrell. 1988. Inhibition of duck hepatitis B virus replication by purine 2′,3′-dideoxynucleosides. Biochem. Biophys. Res. Commun. 156:1144-1151.
48. Tipples, G., M. Ma, K. Fischer, V. Bain, N. Kneteman, and D. Tyrrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
49. Tisdale, M., S. Kemp, N. Parry, and B. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus typel resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
50. Wang, X., and J. Hu. 2002. Distinct requirement for two stages of protein-primed initiation of reverse transcription in hepadnaviruses, J. Virol. 76:5857-5865.
51. Wong, D., A. Cheung, K. O'Rourke, C. Naylor, A. Detsky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 119:312-323.
52. Xiong, X., C. Flores, H. Yang, J. Toole, and C. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
53. Xiong, X., H. Yang, C. Westland, R. Zou, and C. Gibbs. 2000. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 31:219-224.
54. Yamamoto, T., S. Litwin, T. Zhou, Y. Zhu, L. Condreay, P. Furman, and W. S. Mason. 2002. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J. Virol. 76:1213-1223.
55. a. Ying, C., E. De Clercq, W. Nicholson, P. Furman, and J. Neyts. 2000. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J. Viral Hepat. 7(2):161-165
56. Zhou, T., J. Saputelli, C. E. Aldrich, M. Deslauriers, L. D. Condreay, and W. S. Mason. 1999. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob. Agents Chemother. 43:1947-1954.
57. Zhu, Y., T. Yamamoto, J. Cullen, J. Saputelli, C. E. Aldrich, D. S. Miller, S. Litwin, P. A. Furman, A. R. Jilbert, and W. S. Mason. 2001. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75:311-322.
58. Zoulim, F., and C. Seeger. 1995. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.